MaxCyte [MXCT] vs Nevro [NVRO] Detailed Stock Comparison

MaxCyte Inc.

NASDAQ
Loading...

Nevro Corp.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: MaxCyte Inc. wins in 9 metrics, Nevro Corp. wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric MaxCyte Inc. Nevro Corp. Better
P/E Ratio (TTM) -2.07 144.40 Nevro Corp.
Price-to-Book Ratio 0.55 0.96 MaxCyte Inc.
Debt-to-Equity Ratio 10.46 108.86 MaxCyte Inc.
PEG Ratio 0.21 -2.26 MaxCyte Inc.
EV/EBITDA -0.20 -2.15 MaxCyte Inc.
Profit Margin (TTM) -135.14% -27.77% Nevro Corp.
Operating Margin (TTM) -94.81% -21.79% Nevro Corp.
Return on Equity -23.63% -43.29% MaxCyte Inc.
Return on Assets (TTM) -12.60% -9.95% Nevro Corp.
Free Cash Flow (TTM) $-36.18M $-29.23M Nevro Corp.
1-Year Return -49.09% -56.06% MaxCyte Inc.
Price-to-Sales Ratio (TTM) 2.88 0.55 Nevro Corp.
Enterprise Value $7.89M $180.16M Nevro Corp.
EV/Revenue Ratio 0.24 0.44 MaxCyte Inc.
Gross Profit Margin (TTM) 77.95% 62.45% MaxCyte Inc.
Revenue per Share (TTM) $0 $11 Nevro Corp.
Earnings per Share (Diluted) $-0.42 $-3.06 MaxCyte Inc.
Beta (Stock Volatility) 1.45 0.82 Nevro Corp.
Short % of Float 5.23% N/A N/A

MaxCyte Inc. vs Nevro Corp. Stock Performance Analysis

Loading Price Chart...

MXCT
NVRO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
MaxCyte Inc.3.57%0.87%11.54%43.21%-22.15%-25.16%
Nevro Corp.0.00%N/AN/AN/AN/AN/A

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
MaxCyte Inc.-49.09%-77.10%-93.41%-93.41%-93.41%-93.41%
Nevro Corp.-56.06%-92.38%-94.65%-89.12%-76.92%-76.92%

Performance & Financial Health Analysis: MaxCyte Inc. vs Nevro Corp.

MetricMXCTNVRO
Market Information
Market Cap i$92.07M$224.09M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i734,6961,058,636
90 Day Avg. Volume i895,7591,147,389
Last Close$1.16$5.84
52 Week Range$0.64 - $2.37$3.16 - $13.84
% from 52W High-51.05%-57.80%
All-Time High$17.44 (Jul 26, 2021)$188.14 (Dec 21, 2020)
% from All-Time High-93.35%-96.90%
Growth Metrics
Quarterly Revenue Growth-0.16%-0.09%
Quarterly Earnings Growth-0.16%-0.09%
Financial Health
Profit Margin (TTM) i-1.35%-0.28%
Operating Margin (TTM) i-0.95%-0.22%
Return on Equity (TTM) i-0.24%-0.43%
Debt to Equity (MRQ) i10.46108.86
Cash & Liquidity
Book Value per Share (MRQ)$1.61$6.11
Cash per Share (MRQ)$0.96$7.72
Operating Cash Flow (TTM) i$-34,410,000$-19,439,000
Levered Free Cash Flow (TTM) i$-15,469,750$-4,766,875
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: MaxCyte Inc. vs Nevro Corp.

MetricMXCT (Apr 24, 2026)NVRO (May 17, 2025)
Price Ratios
P/E Ratio (TTM) i-2.07144.40
Forward P/E i-3.33-2.26
PEG Ratio i0.21-2.26
Price to Sales (TTM) i2.880.55
Price to Book (MRQ) i0.550.96
Market Capitalization
Market Capitalization i$92.07M$224.09M
Enterprise Value i$7.89M$180.16M
Enterprise Value Metrics
Enterprise to Revenue i0.240.44
Enterprise to EBITDA i-0.20-2.15
Risk & Other Metrics
Beta i1.450.82
Book Value per Share (MRQ) i$1.61$6.11

Financial Statements Comparison: MaxCyte Inc. vs Nevro Corp.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMXCT (2025)NVRO (2024)
Revenue/Sales i33.03M408.52M
Cost of Goods Sold i6.22M138.99M
COGS % of Revenue i18.8%34.0%
Gross Profit i26.80M269.53M
Gross Margin i81.2%66.0%
Research & Development i20.82M51.51M
Operating Income (EBIT) i-45.29M-94.70M
Operating Margin i-137.1%-23.2%
EBITDA i-33.53M-67.70M
EBITDA Margin i-101.5%-16.6%
Pre-Tax Income i-44.63M-112.35M
Pre-Tax Income % of Revenue i-135.1%-27.5%
Income Tax i01.09M
Income Tax % of Revenue i0.0%0.3%
Net Income (Profit) i-44.63M-113.44M
Profit Margin i-135.1%-27.8%

Balance Sheet & Liquidity Metrics

MetricMXCT (2025)NVRO (2024)
Cash & Equivalents i20.07M94.54M
Total Current Assets i118.37M476.00M
Total Current Assets % of Revenue i358.4%116.5%
Total Current Liabilities i14.27M102.94M
Total Current Liabilities % of Revenue i43.2%25.2%
Long-Term Debt i16.49M213.19M
Long-Term Debt % of Revenue i49.9%52.2%
Total Shareholders Equity i171.49M231.01M
Retained Earnings i-261.48M-812.85M
Retained Earnings % of Revenue i-791.7%-199.0%
Property, Plant & Equipment i12.84M36.77M

Cash Flow Statement Comparison

MetricMXCT (2025)NVRO (2024)
Operating Cash Flow i-35.79M-25.99M
Operating Cash Flow % of Revenue i-108.4%-6.4%
Capital Expenditures i-1.77M-9.79M
Free Cash Flow i-36.18M-29.23M
FCF Margin i-109.5%-7.2%
Debt Repayment iN/A0
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMXCTNVRO
Shares Short i5.55MN/A
Short Ratio i5.36N/A
Short % of Float i5.23%N/A
Shares Outstanding i106.79M37.82M
Float Shares i105.71M34.23M
% Held by Insiders i1.40%2.84%
% Held by Institutions i65.81%110.59%
% Held by Public i32.79%-13.43%

Dividend Analysis & Yield Comparison: MaxCyte Inc. vs Nevro Corp.

MetricMXCTNVRO
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A